This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL

This study has been withdrawn prior to enrollment.
(Funding will not be provided for the drug)
Information provided by:
AHS Cancer Control Alberta Identifier:
First received: December 19, 2006
Last updated: February 12, 2016
Last verified: July 2007
The purpose of this study is to see how well Zevalin works in the treatment of low grade indolent B-cell lymphoma when given to patients who have not had any previous treatment for their lymphoma and who otherwise would be followed on a "watch & wait" policy.

Condition Intervention Phase
Lymphoma Drug: 90Y-ibritumomab tiuxetan (Zevalin) Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Previously Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

Resource links provided by NLM:

Further study details as provided by AHS Cancer Control Alberta:

Primary Outcome Measures:
  • Response

Secondary Outcome Measures:
  • Progression free survival

Enrollment: 0

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • histologically confirmed indolent lymphoma including:

    • follicular grade 1 or 2
    • small lymphocytic
    • marginal zone (nodal)
    • marginal zone (splenic)
    • mucosa associated lymphoid tissue (MALT)
  • no evidence of transformation
  • Stage III or IV disease
  • No prior therapy
  • involvement by less than 25% of bone marrow on assessment of trephine biopsy
  • absolute lymphocyte count ≤ x 109/L
  • platelets ≥ 150 x 109/L
  • hemoglobin ≥ 100g/L
  • absolute neutrophil count ≥ 1.5 x 109/L
  • at least one bidimensionally measurable lesion at least 2cm by CT scanning

Exclusion Criteria:

  • any other anticancer treatment for NHL
  • prior radiation therapy
  • prior myeloablative therapy (bone marrow or peripheral blood stem cell transplant)
  • no other malignancy within the past 10 years except adequately treated non-melanoma skin tumors or carcinoma in situ of the cervix
  • presence of central nervous system lymphoma
  • patients known to be HIV positive
  • patients with known seropositivity for Hepatitis C virus, Hepatitis B virus or other active infection uncontrolled by treatment
  • patients with abnormal liver function: total bilirubin > 1.5X ULN or ALT > 2.5X ULN
  • patients with abnormal renal function: serum creatinine > 2.5X ULN
  • known hypersensitivity to murine antibodies or proteins
  • immunotherapy during the preceding 6 months (including monoclonal antibodies, interleukins, interferon)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00414089

Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1X2
Sponsors and Collaborators
AHS Cancer Control Alberta
Principal Investigator: Andrew Belch, MD AHS Cancer Control Alberta
  More Information Identifier: NCT00414089     History of Changes
Other Study ID Numbers: HE-10-0100
Study First Received: December 19, 2006
Last Updated: February 12, 2016

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on June 23, 2017